ENLV

Real-time Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.

Clinical Trial Enrollment Completed: Enlivex Therapeutics has completed patient enrollment for the Phase II stage of its trial for Allocetra™ in treating moderate to severe knee osteoarthritis, with 133 patients randomized and treated. The company anticipates topline data by August 2025.

Osteoarthritis Impact: Osteoarthritis is a prevalent condition affecting over 32.5 million Americans, leading to significant disability and hospitalizations, highlighting the urgent need for effective treatments as current options do not halt joint damage progression.

TMJ Osteoarthritis Overview: Temporomandibular joint (TMJ) osteoarthritis is a common degenerative disease affecting 5-12% of the global population, causing pain and stiffness in the jaw with no long-term effective treatments currently available.

Clinical Trial Announcement: Enlivex Therapeutics has initiated a Phase I trial to evaluate the safety and efficacy of Allocetra™ for treating TMJ osteoarthritis, with the first patient successfully dosed, aiming to recruit six patients who have not responded to conventional therapies.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Investor Webinar Announcement: Enlivex Therapeutics is hosting a live investor webinar on March 5, 2025, to discuss positive interim results from its Allocetra™ trial for knee osteoarthritis, showing significant pain reduction and improved joint function in patients.

Promising Trial Results: The interim data indicates a 47% average reduction in pain and a 46% improvement in joint function at six months post-treatment, with no serious adverse events reported, highlighting Allocetra™'s potential as a breakthrough therapy.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Clinical Trial Announcement: Enlivex Therapeutics has received approval from the Israeli Ministry of Health to start a Phase I trial for Allocetra™ in patients with temporomandibular joint (TMJ) osteoarthritis, aiming to assess its safety and initial efficacy.

Background on TMJ Osteoarthritis: TMJ disorders affect 5-12% of the global population, leading to significant pain and functional impairment, with current treatments often failing to provide long-term relief.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Positive Trial Results: Enlivex Therapeutics announced promising interim efficacy data from its Phase I trial of Allocetra™ for treating moderate to severe knee osteoarthritis, showing significant reductions in pain and improvements in joint function after three months.

Next Steps in Research: The company is progressing to the Phase II stage of the trial, which will further evaluate the safety and efficacy of Allocetra™ through a double-blind, randomized, placebo-controlled study.

Financial Performance: Enlivex Therapeutics Ltd. reported a net loss of $9.8 million for the nine months ending September 30, 2024, an improvement from a loss of $19.97 million the previous year, but faced a decrease in total assets from $36.8 million to $29.8 million.

Challenges: The company's financial struggles are attributed to ongoing difficulties in managing operating expenses, particularly in research and development.

Biotech Companies Investing in Bitcoin: Acurx Pharmaceuticals, Hoth Therapeutics, and Enlivex Therapeutics are planning to invest up to $1 million each in Bitcoin, inspired by MicroStrategy's success, despite being early-stage microcap companies with significant volatility and losses.

Market Speculation and Risks: While institutional interest in Bitcoin is growing, the potential for a speculative bubble remains, reminiscent of past market behaviors, leading to concerns about future volatility and the sustainability of Bitcoin's value as a treasury reserve asset.

Enlivex Therapeutics Bitcoin Investment: Enlivex Therapeutics has approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy, viewing it as a strong treasury reserve asset amid growing institutional acceptance and demand for cryptocurrency.

Company Overview: Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, which aims to restore immune system balance by reprogramming macrophages to their homeostatic state.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Clinical Trial Update: Enlivex Therapeutics has initiated the Phase II stage of its Allocetra™ trial for knee osteoarthritis, enrolling the first 10 patients after receiving approval from regulatory bodies and a positive recommendation from the Data and Safety Monitoring Board.

Osteoarthritis Context: Osteoarthritis is a prevalent condition affecting millions globally, with no current FDA or EMA approved treatments that can halt or reverse its progression, highlighting the critical need for effective therapies like Allocetra™.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Clinical Trial Progress: Enlivex Therapeutics has received authorization from the Danish Medicines Agency to advance to Phase II of its clinical trial for Allocetra™ in treating moderate to severe knee osteoarthritis, following a positive recommendation from the Data and Safety Monitoring Board.

Osteoarthritis Overview: Osteoarthritis is a prevalent condition affecting millions globally, with significant implications for joint health and mobility, highlighting the urgent need for effective treatments as current options do not halt disease progression.

Clinical Trial Progress: Enlivex Therapeutics has received approval from the Data and Safety Monitoring Board to advance to Phase II of its clinical trial for Allocetra™, following a successful Phase I safety run-in that reported no serious adverse reactions in patients with knee osteoarthritis.

Osteoarthritis Impact: Osteoarthritis is a prevalent condition affecting millions globally, with significant implications for joint health and mobility, highlighting the urgent need for effective treatments as current options do not address disease progression.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.